Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Sabirnetug (ACU193) in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
INTERCEPT-AD & ALTITUDE-AD trials. 5/8/24- First patient dosed. Presented at AD/PD & AAN'25. 3/26/25- Completed enrollment ahead of schedule. 8/12/25- Topline data in late 2026. 11/17/25- First patient dosed in Ph2 OLE study. 03/03/26:- New ALTITUDE-AD biomarker and brain-delivery data to be presented at AD/PD March 17-21, 2026. 03/17/26:- ALTITUDE-AD enrolled 542; topline results expected Late 2026 (NCT06335173). 03/26/26:- AD/PD and CTAD 2025 presentations showed sabirnetug biomarker responses and recruitment analyses; ALTITUDE-AD topline remains expected Late 2026. 05/12/26:- ALTITUDE-AD topline results for early AD remain expected in Late 2026. 07/07/26:- ALTITUDE-AD patient-perspective findings to be presented at AAIC July 14, 2026; topline still Late 2026. 07/15/26:- AAIC 2026 posters shared ALTITUDE-AD patient-experience data; topline still expected Late 2026. 08/12/26:- ALTITUDE-AD readout preparations continue. Topline results for the Phase 2 trial will be reported in Late 2026.
Verification
Confirm timing and program details against the company announcement or filing.